Introduction 

There are three key symptoms present in Felty's syndrome, an uncommon and potentially dangerous disorder: rheumatoid arthritis (RA), enlarged spleen, and neutropenia (low white blood cell count). While some individuals with Felty's syndrome have no symptoms at all, others may develop severe, sometimes fatal illnesses.¹ The  American doctor Augustus Felty at Johns Hopkins Hospital documented five rare patients who shared splenomegaly, severe leukopenia, and persistent arthritis lasting around four years. Hanrahan and Miller first used the term Felty's syndrome in 1932, when they talked about the beneficial results of a splenectomy in a person whose features matched those of the five cases that Felty had recorded.² In addition to the three symptoms mentioned above, Felty's syndrome can also cause fatigue, fever, weight loss, skin discolouration in certain areas, a moderately expanded liver, swelling of lymph nodes, Sjögren syndrome, vasculitis, ulcers in the lower extremities, and other outcomes.¹ 

Genetics of felty’s syndrome

More than 90% of individuals with Felty's syndrome have a positive HLA-DR4 test, suggesting a high hereditary tendency to this particular HLA subtype. Felty's syndrome (FS) is caused by HLA-DRB1 alleles, namely HLA-DRB1-04. These alleles are correlated with severe and erosive RA.² Again, patients with Felty's syndrome have been shown to have somatic mutations in the STAT3 gene, which may indicate a common pathogenic mechanism.³ The autoimmune component of Felty's syndrome is impacted by hereditary factors, although the precise genes and processes underlying the condition are yet unknown. According to family research, Felty's syndrome may be inherited as an autosomal dominant feature.⁴

Rarity and demographics

At the same time, the current provisions of the statistics indicate that the approximate prevalence of FS complications in patients with RA is 10 per 100,000 people, or 1-3% of patients. This average number is much lower than the frequency of the onset of clinical FS with systemic lupus erythematosus, which is 52 occurrences per 100,000 people. There is not much information available on Felty’s syndrome globally. Since many Felty’s syndrome patients are asymptomatic, it is not feasible to quantify the true incidence of Felty’s syndrome in rheumatoid arthritis. Evidence suggests that the global incidence of Felty’s syndrome is declining as a result of the extensive use of immunosuppressive medications in rheumatoid arthritis. Felty’s syndrome is said to be rare in African-American patients, with Caucasians having a greater risk of being affected.⁵

Pathophysiology of felty’s syndrome

The pathophysiology of Felty’s syndrome is not well understood and may be multifactorial, comprising both humoral and cellular immunological pathways. For a patient, the fact that their immune activation index was normal during both splenomegaly and neutropenia helped explain why increasing sequestration of neutrophils from a proliferating spleen, plus decreases in these cells by cytotoxic lymphocytes seeding them out of bone marrow, would counterbalance effects on circulating immune complexes.²  

Relationship to rheumatoid arthritis (RA)

Peptidylarginine deaminase 4 (PAD-4) has a role in the pathophysiology of FS and is directly linked to an elevated risk of RA. An essential enzyme in the onset and course of rheumatoid arthritis, PAD-4 affects how severe the condition is as well as the immune system's reaction.⁶ Patients with rheumatoid arthritis may have higher levels of PAD-4 expression in comparison to healthy persons, highlighting the link between the two disorders. Also, about 1–3% of RA patients acquire FS, indicating a strong correlation between the two diseases. 

Immunological basis

The pathogenesis of Felty's syndrome involves the spleen in a major way. A factor in the neutropenia seen in patients is splenic sequestration of neutrophils, which leads to a greater lysis of these cells. Research shows that granulocyte levels in the splenic vein are lower than in the splenic artery, indicating that the spleen is where neutrophil destruction occurs.²

The immune systems involved in Felty's syndrome are both cellular, which are mediated by T-cells, while the humoral immunity is mediated by antibodies. Reduced neutrophil counts are a consequence of the dysregulation of neutrophil survivability and proliferation caused by autoantibodies and circulating immune complexes.

Autoantibodies, such as those directed against granulocyte colony-stimulating factors (G-CSF), are frequently developed by patients with Felty's syndrome. These antibodies can neutralise G-CSF, a crucial cytokine that causes neutropenia, by inducing the generation of neutrophils inside cells of the bone marrow.² 

Consequences of felty’s syndrome

One of the primary causes of mortality and morbidity in Felty’s syndrome is recurrent and severe infections. Additional risks include:

• Neutropenia which is the low level of neutrophils needed to fight against infections. This  increases the chance of bacterial infections, especially those of the skin, lungs, and circulation
• Splenomegaly- an enlarged spleen is one of the hallmarks of Felty’s syndrome. There might be discomfort in the abdomen and a higher chance of splenic rupture
• Hepatic problems are common, so tests for liver function may be abnormal
• Skin ulcers caused by vasculitis, especially on the lower legs
• Hematologic issues such as anaemia are a frequent consequence of rheumatoid arthritis, and they might be more serious than usual. 
• Thrombocytopenia, which is low levels of factors needed for blood clot
• There are also risks involving complications of the human eye in the form of scleritis, episcleritis, and other eye problems
• There is a heightened likelihood of cardiovascular events and accelerated atherosclerosis
• Lymphadenopathy, which is seen as enlarged lymph nodes
• Neurological complications are associated with Felty’s syndrome, but the relationship has not been clearly investigated
• A higher incidence of lymphomas, along with other hematologic malignancies, indicates an elevated risk of cancer
• In 15–40% of FS patients, joint involvement is absent, but if involvement of joints and synovial inflammation is present, they are much more advanced 

While clinical symptoms are often evident in local or systemic infections, the cutaneous and pulmonary tracts are the most prevalent sites of infection.⁷

Management strategies 

Felty’s syndrome is treated with supportive care and treatment of symptoms. Treatment for rheumatoid arthritis must be the same as it would be if Felty’s syndrome were not present, which includes bed rest, sensible activity, heat treatments, gold salts, nonsteroidal anti-inflammatory drugs (NSAIDS), penicillamine, and other medications.

A splenectomy, the removal of the spleen, may be part of the therapy in many circumstances. Anaemia, thrombocytopenia, neutropenia, and persistent infections that are frequently linked to Felty syndrome have all benefited from stem cell transplantation. The medical literature suggests that there is now uncertainty over the procedure's long-term benefits.⁴

Treatment of neutropenia

The management of Felty’s syndrome includes the following:

• Hematopoietic growth factors and immunosuppressive medications 
• The potent antitubercular drug methotrexate (Rheumatrex, Trexall) is also used as an immunosuppressant
• Cyclophosphamide is an immunosuppressive and antineoplastic alkylating agent
• The generation, maturation, and activation of neutrophils are stimulated by hematopoietic growth factors
• Filgrastim treats infections that don't improve with medication
• Sargramostim-  48–91% of FS patients had higher granulocyte counts
• Monoclonal antibodies and antineoplastics target proteins involved in the start of the cell cycle
• A genetically modified antibody called Rituximab (Rituxan) targets the CD20 antigen on both healthy and cancerous B cells
• Low doses of corticosteroids, hydroxychloroquine, rituximab, and methotrexate

Long-term outcomes 

The major complication of FS is the susceptibility to bacterial infections, with the skin, oral, and respiratory tracts being the common organs involved. Patients with Felty's syndrome are highly susceptible to life-threatening infections (like pneumonia), putting them at a much greater risk of morbidity and mortality, mostly caused by neutropenia, which renders the patient unable to fight off various harmful organisms. Research shows that infection is the most common cause of mortality in Felty’s syndrome patients.

Research advancements and emerging therapies

Since Felty's syndrome is so rare, it is challenging to run large clinical trials on new therapies. This is based on a review of existing literature (mostly case reports and small case series). Further studies are necessary to better understand the genetic and immunological processes underlying the pathophysiology of Felty's syndrome and to improve strategies for personalised medicine. A better definition of the interplay between rheumatoid arthritis, neutropenia, and splenomegaly in Felty's syndrome may help refine diagnostic criteria or prognostic markers.

Summary

Recurrent and severe infections, splenomegaly, hepatic involvement, skin ulcers, hematologic problems, ophthalmic symptoms, cardiovascular consequences, lymphadenopathy, osteoporosis, peripheral neuropathy, and an increased risk of cancer are the hallmarks of the uncommon illness known as Felty’s syndrome. There is a high vulnerability to bacterial infections, especially neutropenia, which is the most prevalent cause of death in people with Felty’s syndrome and is one of the long-term consequences.

The treatment options for it include stem cell transplantation, splenectomy, and rheumatoid arthritis, among other symptomatic treatments. Hematopoietic growth factors, immunosuppressive drugs, methotrexate, cyclophosphamide, and filgrastim are examples of medicinal therapies.